[Re: https://www.hifa.org/dgroups-rss/spotlight-group-b-strep-29-results-deve... ]
Very interesting questions you raise, Neil. Thank you for bringing up the comprehensive table of countries’ approaches to GBS screening. We (Group B Strep International) have compiled our own internal table based off of this supplemental review which can be found at https://drive.google.com/file/d/1D-bhH46AjA-ijNSOCqXgyUnhHMZVkVOQ/ for this article: [*see note below]
Le Doare K, O'Driscoll M, Turner K, Seedat F, Russell NJ, Seale AC, Heath PT, Lawn JE, Baker CJ, Bartlett L, Cutland C, Gravett MG, Ip M, Madhi SA, Rubens CE, Saha SK, Schrag S, Sobanjo-Ter Meulen A, Vekemans J, Kampmann B; GBS Intrapartum Antibiotic Investigator Group. Intrapartum Antibiotic Chemoprophylaxis Policies for the Prevention of Group B Streptococcal Disease Worldwide: Systematic Review. Clin Infect Dis. 2017 Nov 6;65(suppl_2):S143-S151. doi: 10.1093/cid/cix654. PMID: 29117324; PMCID: PMC5850619.
Will check further on making our internal table available for others to update and contribute to.
Best,
Marti
(Ms.) Marti Perhach
CEO/Cofounder
Group B Strep International
+1 909 620-7214
marti.perhach@gbs-intl.org
www.groupbstrepinternational.org
CHIFA profile: Marti Perhach is CEO/Cofounder of Group B Strep International, United States. Professional interests: Group B strep disease research and prevention, prenatal infection, One Health. www.groupbstrepinternational.org Email address: marti.perhach AT gbs-intl.org
[*Note from HIFA moderator (NPW): Thanks Marti, I have put in a request to view/edit this google doc and look forward to see how it can be developed further]